ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Why Inspire Medical Systems (INSP) Stock Is Trading Up Today

INSP Cover Image

What Happened?

Shares of medical technology company Inspire Medical Systems (NYSE: INSP) jumped 16.2% in the morning session after the company reported strong third-quarter results that significantly surpassed Wall Street's expectations for both revenue and profit. 

For the quarter, Inspire Medical announced revenue of $224.5 million, up 10.5% year-on-year, topping analysts' forecasts. The company delivered a significant surprise on profitability, posting a GAAP profit of $0.34 per share, which was well above analyst estimates of a $0.19 per share loss. Management highlighted that growth was primarily driven by increased patient volume, positive clinical feedback, and continued expansion of the U.S. and international customer base. Bolstering investor confidence, the company reconfirmed its full-year revenue guidance of $905 million and provided full-year earnings guidance of $0.95 per share, also beating expectations. The strong report was a welcome sign for investors, suggesting a potential stabilization of the business after a weak second quarter.

Is now the time to buy Inspire Medical Systems? Access our full analysis report here.

What Is The Market Telling Us

Inspire Medical Systems’s shares are extremely volatile and have had 31 moves greater than 5% over the last year. But moves this big are rare even for Inspire Medical Systems and indicate this news significantly impacted the market’s perception of the business.

The previous big move we wrote about was 11 days ago when the stock dropped 3.4% on the news that Jefferies downgraded the stock to Hold from Buy and sharply reduced its price target to $85 from $160. The downgrade followed the firm's U.S. sleep survey, which pointed to ongoing headwinds from the uptake of GLP-1 weight loss medications and market share gains by competitors. The analyst also noted "muted expectations" for volume growth related to the company's Inspire 5 product line. Other contributing factors included concerns about physician reimbursement and what was described as a recent history of "execution challenges" at the medical device company.

Inspire Medical Systems is down 54.6% since the beginning of the year, and at $86.20 per share, it is trading 60% below its 52-week high of $215.42 from January 2025. Investors who bought $1,000 worth of Inspire Medical Systems’s shares 5 years ago would now be looking at an investment worth $517.53.

Do you want to know what moves the business you care about? Add them to your StockStory watchlist and every time a stock significantly moves, we provide you with a timely explanation straight to your inbox. It’s free for active Edge members and will only take you a second.

Recent Quotes

View More
Symbol Price Change (%)
AMZN  234.69
-2.89 (-1.22%)
AAPL  272.41
-0.54 (-0.20%)
AMD  246.81
-1.15 (-0.46%)
BAC  52.61
-0.26 (-0.49%)
GOOG  276.98
-2.14 (-0.77%)
META  609.46
-0.43 (-0.07%)
MSFT  510.18
+6.89 (1.37%)
NVDA  190.17
+3.31 (1.77%)
ORCL  222.85
+5.28 (2.43%)
TSLA  404.35
+2.36 (0.59%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.